Ironwood discontinued U.S. commercialization of lesinurad (DUZALLO and ZURAMPIC) effective February 1, 2019. This was a business decision and was not related to any efficacy, safety or clinical concerns with lesinurad. If you have been taking either DUZALLO or ZURAMPIC to treat your condition, please consult with your healthcare professional before making any decisions to stop treatment. Please work with your healthcare professional for an alternate treatment for your condition.
The DUZALLO and ZURAMPIC Patient Savings Program was discontinued effective December 31, 2018.
We regret any inconvenience this may cause.
For inquiries about DUZALLO or ZURAMPIC, or to report an adverse event, possible side effect, or product quality concern/issue regarding DUZALLO or ZURAMPIC, please contact Ironwood via the Contact Us On-Line Form available by clicking on this link: (https://contactus.irwdpi.com/) or call the Ironwood Contact Center at 1-844-374-4793.
Alternatively, you can report any side effects of prescription drugs directly to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.